Fig. 3

Delivery of Tet-29 after established disease still exerts a disease modifying effect. Female C57Bl/6J mice were immunised for EAE. Treatment with 30 mg/kg/day of Tet-29 or the equivalent volume of vehicle began at disease onset, defined as a disease score of  ≥ 1, and continued for at least 20 days. Mice were scored daily (a, b) and days spent in relapse were recorded (c). Relapse was defined as an increase in score of  ≥ 0.5 for ≥ 2 days. d–g Infiltration of T cells into the spinal cord was investigated by flow cytometry. All data are displayed as mean ± SEM and are pooled from 4 independent experiments, n = 18–28 per group. a ****p < 0.0001 by mixed effects ANOVA and *p < 0.05, **p < 0.01 by Sidak’s multiple comparison test. b, c *p < 0.05 by Student’s unpaired t-test. d–g *p < 0.05, **p < 0.01, ***p < 0.001 by one-way ANOVA with Tukey’s multiple comparisons